Four weeks is about eight per cent short of a month
Each of the three product cards states that the figure buys four weeks of medicine, or four packs in the case of the oral product. A calendar month averages a little over thirty days; four weeks is twenty-eight.
Over a year that difference is about an extra fill. We have recorded all three rows as not monthly with the arithmetic in the qualifier, so no page on this site can print a per-month suffix beside a figure the seller measures in weeks.
Twenty-six of the one hundred and fifty-eight sellers here carry at least one figure that is not a monthly rate. Being explicit about the unit, as this seller is, is the good version of that.
A celebrity on the price block
The page's opening line invites the reader to try the same programme as a named television actor, with the starting figure attached directly beneath. The endorsement is the pitch, not a footnote.
Nothing on the page says whether the endorsement is paid, whether the person is a customer, or what the relationship is. A reader weighing a medical purchase on a personal recommendation is entitled to know which of those it is.
Each card also claims that a five-figure number of patients chose that product today. Read literally, that would be a larger daily volume than most of this roster serves in a year. It is an urgency device, and it is the kind of number that makes the honest parts of a page harder to trust.
An oral product with no named molecule
The third card is an oral GLP-1 sold in packs. Neither the card nor the page names which molecule it contains. Twenty of the one hundred and fifty-eight sellers here put a price beside a product they will only call a GLP-1.
The privacy policy names a corporation throughout, and that corporation's name shares nothing with the brand. Nothing called Velvet appears as an entity anywhere on it.
No pharmacy is named, no individual clinician is named, and no service area is published.
Velvet Rx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $99the card states the price buys "4 weeks of medicine", which is twenty-eight days and not a calendar month - about eight per cent short of one - and the figure is struck against $299. The card also states it includes the doctor consult, unlimited one-to-one medical support, the written prescription and free shipping | September 2026source |
| Tirzepatide (compounded) | $179same four-week unit, struck against $359 | September 2026source |
| Glp-1 (compounded-oral) | $149the oral product, sold as "4 packs of medicine" rather than a month, struck against $349; the seller does not name which molecule the oral product contains | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Velvet Rx's current price →Good fit if
- Readers who want a seller to state exactly how many weeks of medicine a figure buys.
- Buyers who want the consult and the support listed as part of the price.
- People comparing an oral option against two injections at published figures.
Look elsewhere if
- Anyone budgeting per calendar month; these prices are per four weeks.
- Readers who want to know whether a celebrity endorsement is paid.
- Buyers who need to know which molecule an oral product contains.
- People who want the brand and the legal entity to share a name.
How this review was verified
- Read the homepage and the privacy policy on 6 September 2026, with a nonsense-path control on the host in the same run that returned a clean not-found status.
- Recorded the unit the seller states — four weeks of medicine, four packs — rather than treating any figure as monthly.
- Joined adjacent text nodes before matching prices; each card renders its struck price and its offer price as one run of characters with no separator.
- Read the privacy policy for an entity carrying the brand name and found none; the corporation it does name is recorded instead.
- Screened the operating entity and the brand name against FDA's live warning-letter datatable, carrying a known letter as a positive control and a nonsense string as a negative control in the same pass; the positive control returned its letter and the negative returned nothing. Neither the entity nor the brand returned one. Untitled letters are published separately and were not searched, so the supportable claim is that no warning letter was found.